Highest-materiality recent filing
Cyclerion shareholders approve merger proposals; 1-for-7 reverse split; redomestication fails
Shareholders approved Nasdaq issuance, authorized share increase to 700M, reverse split, and 2026 stock plans; redomestication to Cayman failed.
Cyclerion sets Sept 4, 2026 record date for CVR distribution in Korsana merger
Record date of Sept 4, 2026 fixed for contingent value rights (CVRs) to holders of common stock and Series A Preferred.
Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets
Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.
Received positive pre-IND written feedback from FDA supporting CYC-126 Phase 2 POC study design in treatment-resistant depression (TRD).
Cyclerion Therapeutics enters collaboration with Medsteer for CYC-126 anesthetic delivery system
Cyclerion entered a Collaboration and Option Agreement with Medsteer for an anesthetic delivery system for treatment-resistant depression.
Cyclerion to receive $1M milestone if Akebia doses first patient in Phase 2 FSGS trial
Akebia announced Phase 2 trial initiation for Praliciguat in FSGS; first patient dosing expected in 2026.
Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.
Cyclerion shareholders elect all six director nominees at annual meeting
All six director nominees elected with >1.3M votes for each; broker non-votes 743,285.
Cyclerion enters $20M ATM equity distribution agreement with Guggenheim
Entered Sales Agreement with Guggenheim Securities for at-the-market offering of up to $20M of common stock.
Cyclerion raises $1.375M in private placement of 499,998 shares at $2.75/sh
Sold 499,998 shares at $2.75 each to insiders Peter Hecht and Michael Higgins.
Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal
Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.
Cyclerion promotes Regina Graul, Ph.D., to CEO and President
Regina Graul, Ph.D., promoted to CEO, President, and Board member effective August 7, 2024.
Cyclerion Therapeutics shareholders re-elect all five directors, ratify Ernst & Young as auditor
Each of five director nominees (De Souza, Hecht, Hyman, Higgins, Katabi) elected with for votes ranging from 1,670,155 to 1,688,966.
Cyclerion sets 2024 annual meeting for June 14, 2024; record date April 17, 2024
Annual meeting to be held on June 14, 2024 in virtual format.
Cyclerion appoints Regina Graul as President; CEO Peter Hecht transitions to strategic consultant
Regina Graul, Ph.D., appointed President effective Dec 1, 2023; CEO Peter Hecht steps down but remains strategic consultant and board member.
Board increased to six members; Higgins and Katabi elected effective Nov 30, 2023, both deemed independent under NASDAQ rules.
Director Ole Isacson resigns from Cyclerion board; replacement to be named
Ole Isacson, M.D., Ph.D., resigned as director effective November 19, 2023.
Cyclerion CFO Anjeza Gjino to resign; separation includes up to $430K in cash payments
CFO Anjeza Gjino to resign after Q3 2023 10-Q filing; resignation not due to any disagreement.
Cyclerion shareholders approve sale of zagociguat/CY3018 assets and CEO stock issuance
Shareholders approved Asset Sale Proposal (95% for) to sell zagociguat (CY6463) and CY3018 programs per May 11 APA.
Cyclerion discloses lawsuit challenging its asset sale; issues supplemental proxy disclosures
One lawsuit and five demand letters allege false/misleading proxy statement for the $8M + 10% stock sale to JW Celtics.
COO Cheryl Gault resigns; effective at close of asset sale to JW Celtics
Cheryl Gault resigned as COO effective on closing of the proposed sale of certain assets to JW Celtics Investment Corp.
Cyclerion regains compliance with Nasdaq minimum bid price requirement
Received formal notice from Nasdaq of regained compliance with $1.00 minimum bid price rule.
Peter Hecht, CEO, purchased $5M in equity at $8.68 per share (post-1-for-20 reverse split).
Cyclerion announces 1-for-20 reverse stock split effective May 15, reduces shares to ~2.18M
1-for-20 reverse split effective 5:00 PM ET May 15; trading begins split-adjusted May 16 under symbol CYCN.
Cyclerion sells zagociguat & CY3018 for $8M cash + 10% equity; CEO to lead NewCo
Receives $8M cash at closing and 10% equity in NewCo with anti-dilution protection through $100M post-money.
Cyclerion enters exclusive talks to sell zagociguat/CY3018; CEO to invest $5M
Non-binding proposal from entity including CEO Peter Hecht to buy zagociguat and CY3018 assets.
Cyclerion reports $44.1M net loss in 2022; cash $13.4M; evaluating options for zagociguat
Cash, equivalents & restricted cash $13.4M at Dec 31, 2022, down from $20.4M at Sep 30, 2022.
Cyclerion gets 180-day bid price extension; transfers to Nasdaq Capital Market
Nasdaq granted extension to May 29, 2023 to regain $1.00 minimum bid price compliance.
Cyclerion board rejects unsolicited CEO-led asset purchase proposal
Unsolicited proposal received Nov 20, 2022 from group including CEO to purchase certain assets.
Cyclerion cuts 45% of workforce, focuses on mitochondrial disease after positive MELAS data
Workforce reduced by ~45% (13 employees) in Q4 2022 to align with mitochondrial disease strategy.
CSO Andreas Busch resigns effective Sept 30, 2022
Andreas Busch, Ph.D. resigned as Chief Scientific Officer, effective Sept 30, 2022.
Cyclerion reports Q2 net loss $13.4M; positive CY6463 data in MELAS and CIAS studies
Cash $30.3M at June 30, 2022; net loss $13.4M vs $16.2M year ago.
Cyclerion CY6463 shows cognition effect size 0.60 in CIAS study; well tolerated
Effect size 0.60 on Cogstate Schizophrenia Battery composite after 14 days of 15 mg CY6463 vs placebo.
Cyclerion appoints Steven E. Hyman to board; former NIMH director and neuroscience leader
Steven Hyman appointed to Board effective July 25, 2022, following Board expansion from 8 to 9 members.
Cyclerion Therapeutics stockholders elect directors and ratify auditor at 2022 annual meeting
Elected eight directors: Conrades, De Souza, Fanucci, Hecht, Isacson, Lovell, McGuire, Mendelsohn; each received over 22.4 million votes for.
Cyclerion (CYCN) reports positive topline data for CY6463 in MELAS study; improvements in biomarkers
Open-label, eight-patient study showed improvements in lactate, GDF-15, inflammatory biomarkers, cerebral blood flow, and functional connectivity after 29 days.
Received Nasdaq deficiency letter on June 1, 2022, for failing minimum $1 bid price for 30 consecutive business days.
Cyclerion reports Q1 net loss $13.0M; CY6463 MELAS data expected Q2 2022
Net loss of $13.0M in Q1 2022 vs $13.4M in Q1 2021; cash balance $41M (down from $54M).
Cyclerion reports FY2021 net loss $51.6M; MELAS topline data expected Q2 2022
Net loss $51.6M for FY2021 vs $77.8M in FY2020; cash $54M at Dec 31, 2021.
Cyclerion reports Q3 net loss $11.3M, cash $63M; pipeline advances in CIAS, ADv, MELAS
Net loss of $11.3M improved from $18.8M in Q3 2020; R&D expenses down to $7.0M.
Cyclerion appoints CEO Peter Hecht as interim CFO during CFO's maternity leave
Peter M. Hecht, CEO, appointed Interim CFO effective October 27, 2021 while Anjeza Gjino is on maternity leave.
Cyclerion updates three CY6463 trials: CIAS Phase 1b enrolled, MELAS topline H1 2022, ADv screening
First patients enrolled in Phase 1b study of CY6463 for cognitive impairment associated with schizophrenia (CIAS).
Director Kevin B. Churchwell resigns from Cyclerion board effective Aug 18, 2021
Kevin B. Churchwell, M.D. resigned from the board of directors on August 18, 2021.
Net loss of $16.2M in Q2 2021 vs $19.5M in Q2 2020; cash $70M as of June 30, 2021, up from $45M in March.
On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) unanimously elected Regina Graul Ph.D., as President of the Company, effective December 1, 2023.
She replaces Peter Hecht, Ph.D., who resigned on November 30, 2023 as President and Chief Executive Officer to pursue his responsibilities as President of Tisento.
On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.
On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.
On November 19, 2023, Ole Isacson, M.D., Ph.D., tendered his resignation as a director of Cyclerion Therapeutics, Inc. (the “Company”), effective immediately.
On October 17, 2023, Cyclerion Therapeutics Inc. (“Cyclerion”) and Anjeza Gjino (“Ms. Gjino”), Cyclerion’s Chief Financial Officer, entered into a Separation and Release of Claims Agreement, dated such date (the “Agreement”), pursuant to which Ms. Gjino will resign from Cyclerion.
On June 26, 2023, Cheryl Gault announced her resignation as the Chief Operating Officer of Cyclerion Therapeutics, Inc.
On and effective September 30, 2022, Andreas Busch, Ph.D. resigned from his position as Chief Scientific Officer of Cyclerion Therapeutics, Inc. (the “Company”) to pursue another opportunity.
Cyclerion Therapeutics, Inc. (the “Company”) has announced that Steven E. Hyman, M.D., was appointed to the Company’s board of directors (the “Board”) on July 25, 2022.
On October 27, 2021, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) temporarily appointed Peter M. Hecht, Ph.D., as Interim Chief Financial Officer (principal financial and accounting officer) of the Company while Anjeza Gjino is on maternity leave.
On and effective August 18, 2021, Kevin B. Churchwell, M.D., resigned from the board of directors of Cyclerion Therapeutics, Inc.
Max materiality 0.90 · Median 0.60 · Most common event other_material